Showing results (381-390 of 414) with videos related to

Sort By:
Pageof 42
Clinical Transplants|January 1, 1996
Update of the Adult and Pediatric Liver Transplant Program at the University of MichiganJ G Turcotte, J C Magee, J S Bromberg, et al.
Gastroenterology|April 2, 2004
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatmentMitchell L Shiffman, Adrian M Di Bisceglie, Karen L Lindsay, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 2, 2021
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP studyMarina Serper, Donna M Evon, Jipcy Amador, et al.
Gastroenterology|August 28, 2016
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic ResponseNorah A Terrault, Stefan Zeuzem, Adrian M Di Bisceglie, et al.
Gastroenterology|December 7, 2010
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis CAnna S Lok, James E Everhart, Elizabeth C Wright, et al.
Plos One|August 2, 2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational studyDonna M Evon, Paul W Stewart, Jipcy Amador, et al.
Hepatology (Baltimore, Md.)|March 18, 2009
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trialAnna S Lok, James E Everhart, Raymond T Chung, et al.
The New England Journal of Medicine|December 5, 2008
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferonAdrian M Di Bisceglie, Mitchell L Shiffman, Gregory T Everson, et al.
Cancer|May 19, 2017
Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapyJessica P Hwang, Maria E Suarez-Almazor, Scott B Cantor, et al.
Journal of General Internal Medicine|October 30, 2019
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting AntiviralsMarina Serper, Donna M Evon, Paul W Stewart, et al.
Pageof 42